Log in

NASDAQ:BNTXBioNTech Stock Price, Forecast & News

+3.83 (+5.85 %)
(As of 07/7/2020 04:00 PM ET)
Today's Range
Now: $69.34
50-Day Range
MA: $53.62
52-Week Range
Now: $69.34
Volume2.26 million shs
Average Volume1.10 million shs
Market Capitalization$15.69 billion
P/E RatioN/A
Dividend YieldN/A
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 for prostate cancer; BNT113 that is in Phase I clinical trial to treat HPV+ head and neck cancers; BNT114, which is in Phase I clinical trial for triple negative breast cancer; and BNT115 and BNT116 to treat other cancers, including ovarian cancer. It also develops individualized neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; next-generation checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company was founded in 2008 and is headquartered in Mainz, Germany.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.90 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:BNTX



Sales & Book Value

Annual Sales$121.63 million
Book Value$2.44 per share



Market Cap$15.69 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive BNTX News and Ratings via Email

Sign-up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter.

BioNTech (NASDAQ:BNTX) Frequently Asked Questions

How has BioNTech's stock been impacted by COVID-19 (Coronavirus)?

BioNTech's stock was trading at $32.17 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BNTX shares have increased by 115.5% and is now trading at $69.34. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of BioNTech?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for BioNTech.

How were BioNTech's earnings last quarter?

BioNTech SE (NASDAQ:BNTX) posted its earnings results on Tuesday, May, 12th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. The business had revenue of $30.51 million for the quarter, compared to analyst estimates of $27.90 million. View BioNTech's earnings history.

What price target have analysts set for BNTX?

8 brokerages have issued 12 month price objectives for BioNTech's stock. Their forecasts range from $21.00 to $63.00. On average, they anticipate BioNTech's share price to reach $43.56 in the next year. This suggests that the stock has a possible downside of 37.2%. View analysts' price targets for BioNTech.

Has BioNTech been receiving favorable news coverage?

News articles about BNTX stock have trended negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. BioNTech earned a news impact score of -2.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about BioNTech.

Who are some of BioNTech's key competitors?

What other stocks do shareholders of BioNTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Moderna (MRNA), Advanced Micro Devices (AMD), Micron Technology (MU), Johnson & Johnson (JNJ), Pfizer (PFE), Regeneron Pharmaceuticals (REGN), Walt Disney (DIS) and NVIDIA (NVDA).

Who are BioNTech's key executives?

BioNTech's management team includes the following people:
  • Prof. Ugur Sahin M.D., CEO & Member of Management Board (Age 54)
  • Dr. Sierk Pötting, CFO, COO & Member of Management Board (Age 46)
  • Mr. Sean Marett, Chief Bus. Officer, Chief Commercial Officer & Member of Management Board (Age 54)
  • Dr. Özlem Türeci, Chief Medical Officer & Member of Management Board (Age 52)
  • Sabine Steimle, Head Global Communications

When did BioNTech IPO?

(BNTX) raised $251 million in an initial public offering on Thursday, October 10th 2019. The company issued 13,200,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink acted as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

What is BioNTech's stock symbol?

BioNTech trades on the NASDAQ under the ticker symbol "BNTX."

How do I buy shares of BioNTech?

Shares of BNTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioNTech's stock price today?

One share of BNTX stock can currently be purchased for approximately $69.34.

How big of a company is BioNTech?

BioNTech has a market capitalization of $15.69 billion and generates $121.63 million in revenue each year. The company earns $-200,540,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis. BioNTech employs 1,310 workers across the globe.

What is BioNTech's official website?

The official website for BioNTech is www.biontech.de.

How can I contact BioNTech?

BioNTech's mailing address is AN DER GOLDGRUBE 12, MAINZ 2M, 55131. The company can be reached via phone at 49-61-31908-40 or via email at [email protected]

This page was last updated on 7/8/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.